– Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend's portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD) – March 27, 2026 -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Transcend Therapeutics, Inc. (Transcend) announce that the two companies entered into an agreement today, under which Otsuka, through its wholly owned subsidiary Otsuka America, Inc., will fully acquire Transcend. The acquisition is e

The US FDA has approved Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat patients 12 years and older with previously untreated stage 3 or 4 cHL. In the EU, approval has been granted by the European Commission (EC) for Opdivo in combination with brentuximab vedotin to treat patients between five and 30 years of age with relapsed or refractory cHL who have already received one prior line of therapy. SWOG 1826, a phase 3 study on which the US FDA based its approv

The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S. UCB is investing $2 billion to build its first biologics manufacturing facility in the U.S., putting down roots in Georgia to support products including the psoriasis drug Bimzelx. Belgium-based UCB unveiled plans to build a biologic

Novartis announced plans to invest more than 3.3 billion yuan (nearly $480 million) to expand its research, production, and operations footprint in China, with a focus on advancing pharmaceutical innovation and radioligand therapy (RLT). According to the announcement , the investment includes the expansion of manufacturing and R&D infrastructure. In Changping, Beijing, the company is upgrading its production site with planned investments of about 1.5 billion yuan (approximately $ 220 million) t

March 26, 2026 -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced that, building on the productive collaboration over the past year, the two parties will further expand and deepen AI-driven R&D

Partnership brings reliable access to a critical cancer therapy isotope to one of the world's largest and fastest-growing oncology markets March 26, 2026 -- SHINE Technologies, LLC today announced a supply agreement with C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, establishing C-Ray as SHINE's exclusive distribution partner for non-carrier-added lutetium-177 (n.c.a. Lu-177) across mainland China, excluding certain pre-existing SHINE partnerships. Under the agreemen

Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed, and the incidence of Grade

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes March 26, 2026 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulino

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver mini-CR1, a potent modulator of multiple pathways of the complement system Opti-GAIN is supported by Pre-GAIN, an ongoing natural history study designed to provide short-term GA progression insights and support the development of novel endpoints March 25, 2026 -- Complement Therapeutics GmbH (CTx), a

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing March 25, 2026 -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results from Phase 1 clinical studies of BGM0504, an investigational oral GLP-1/GIP dual receptor agonist, in adult participants in China and the United States, including healthy volunteers and individuals with overweight or obesity. Across